Prevention And Management Of Dermatological Toxicities Related To Anticancer Agents: ESMO Clinical Practice Guidelines

    November 2020 in “ Annals of Oncology
    Mario E. Lacouture, V. Sibaud, Peter Arne Gerber, Corina van den Hurk, Pablo Fernández‐Peñas, Daniele Santini, Franziska Jahn, Karin Jordan
    TLDR Early intervention and tailored management can reduce skin side effects from cancer treatments.
    The ESMO Clinical Practice Guidelines provided recommendations for preventing and managing dermatological toxicities associated with anticancer agents, such as acneiform rash, hand-foot syndrome, alopecia, pruritus, paronychia, and onycholysis. Dermatological adverse events (AEs) were common in cancer patients undergoing systemic therapies, with targeted therapies causing AEs in 75%-90% of patients and immunotherapies in ≥30%. The guidelines emphasized preventive measures, such as skin care and the use of oral tetracyclines, and therapeutic strategies, including topical and systemic corticosteroids. For chemotherapy-induced alopecia (CIA), scalp cooling was the only method shown to prevent it, with 50%-65% efficacy, and minoxidil 5% was suggested for hair regrowth post-chemotherapy. The guidelines highlighted the importance of early intervention and tailored management strategies to mitigate these side effects and maintain treatment efficacy and quality of life for patients.
    Discuss this study in the Community →

    Research cited in this study

    7 / 7 results

    Related Community Posts Join

    6 / 1000+ results

    Similar Research

    5 / 1000+ results